Digital PCR Market by Product (Instruments, Reagents & Consumables, Software & Services), by Application (Oncology Testing, Infectious Disease Testing, Genetic Disease Testing, Prenatal & Reproductive Testing and Transplant Monitoring), by Technology (Droplet Digital PCR, Chip-Based Digital PCR, Nanoplate-based & microfluidic digital PCR and BEAMing), by End User (Diagnostic Laboratories, Academic & Research Institutes, Pharma & Biotech Companies) and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, 15 Nov 2026 — Vectomat Insights has published a new report titled ‘Digital PCR Market by Product, Application, Technology, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Digital PCR market was valued at USD 1,843.6 Mn in 2025 and is projected to reach USD 5,206.5 Mn by 2035, growing at a CAGR of 10.94% during the forecast period 2026–2035, according to Vectomat Insights.
Droplet digital PCR is the workhorse, taking 61.6% of 2025 revenue, and Bio-Rad's July 2025 launch of four new ddPCR platforms after its Stilla Technologies buyout shows the category leader isn't sitting still.
The Global Digital PCR market was valued at USD 1,843.6 Mn in 2025 and will reach USD 5,206.5 Mn by 2035, a 10.94% CAGR. Instruments hold 44.0% of revenue today, but reagents and consumables overtake them by 2035. North America leads with 41.0%. Oncology testing is the largest application, and infectious disease testing grows fastest at 14.58% a year.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global Digital PCR Market Size, Share, Growth & Forecast By Product, Application, Technology, and End User, 2026–2035 |
| Base Year Market Size | USD 1,843.6 Mn (2025) |
| Forecast Market Size | USD 5,206.5 Mn (2035) |
| CAGR | 10.94% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (41.0%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | Droplet Digital PCR (61.6%) |
| Dominant Application | Oncology Testing |
| Report Format | |
| Publisher | Vectomat Insights |
What Diagnostics Leaders Need to Know About the Digital PCR Market
Clinical Laboratory Directors: Diagnostic laboratories already hold 42.5% of digital PCR revenue, and clinical menus are filling in fast: Biodesix is validating Bio-Rad's ddPLEX ESR1 assay for breast cancer monitoring. Plan for assay-by-assay validation work, not a single platform decision.
Pharma R&D and CGT Quality Heads: Pharma and biotech is the fastest-growing end user at a 15.59% CAGR, rising to USD 2,041.2 Mn by 2035. Vector titre, residual host-cell DNA and lentivirus kits are now off-the-shelf, so qualify a second platform before your release testing scales.
Oncology Service Line Leaders: Oncology testing is the largest application at USD 626.8 Mn in 2025. Roche's planned USD 595 Mn purchase of SAGA Diagnostics, whose Pathlight MRD test pairs sequencing with digital PCR, tells you where monitoring is heading.
Public Health Laboratory Directors: Infectious disease testing grows at 14.58% a year, the fastest of any application, and wastewater programmes run mostly on RT-dPCR. CDC's network now takes data from about 1,500 U.S. sampling sites, so budget for multiplex panels and proficiency testing, not just instruments.
Procurement and Investment Teams: Instruments grow at just 7.0% a year while reagents and consumables compound at 11.92%, so total cost of ownership is set by pull-through, not list price. Three ownership changes in 18 months, from Stilla to QIAGEN, mean contract terms deserve a fresh look.

What Is the Digital PCR Market?
Digital PCR refers to a form of polymerase chain reaction that splits one sample into thousands of tiny partitions, amplifies each one, and counts the positives to give an absolute number of target DNA or RNA copies, with no standard curve. Why does that matter now? Oncologists want to track tumour DNA in blood at very low levels, public health labs run wastewater programmes that need exact counts, and gene therapy makers must prove vector dose batch after batch. Those three buyers are pulling the market from a research niche into routine testing, and they're why spending on reagents, software and service is outgrowing spending on instruments.
How Is the Digital PCR Market Segmented?
Droplet digital PCR owns the technology mix, taking 61.6% of 2025 revenue, or USD 1,136.2 Mn, thanks to the biggest installed base and assay catalogue. But the fastest money isn't in hardware. Software & Services grows at 16.84% a year, and reagents and consumables overtake instruments by 2035. On the application side, oncology testing leads at 34.0%, while infectious disease testing climbs fastest at 14.58%. Pharma and biotech buyers are the end users to watch, compounding at 15.59% on gene therapy release testing. Bio-Rad's QX700 series, with seven-colour multiplexing, shows where platforms are heading.
This report segments the Digital PCR market as follows:
- By Product: Instruments, Reagents & Consumables, Software & Services
- By Application: Oncology Testing, Infectious Disease Testing, Genetic Disease Testing, Prenatal & Reproductive Testing and Transplant Monitoring
- By Technology: Droplet Digital PCR, Chip-Based Digital PCR, Nanoplate-based & microfluidic digital PCR and BEAMing
- By End User: Diagnostic Laboratories, Academic & Research Institutes, Pharma & Biotech Companies
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa

Which Region Leads the Digital PCR Market?
North America is the biggest market by a wide margin, with 41.0% of 2025 revenue, or USD 755.9 Mn. The United States accounts for USD 619.8 Mn of that, helped by CDC-funded wastewater programmes and clinical oncology labs. Europe comes second at 24.74%, led by Germany's USD 119.5 Mn market and home to both QIAGEN and Stilla. Asia Pacific, at 23.81%, is the fastest-growing region; South Korea is compounding at 13.1% a year with state-backed platform programmes. Latin America holds 5.0%, the Middle East 3.07% and Africa 2.38%, where public health surveillance is the main way in.

Why Is the Digital PCR Market Growing?
Liquid Biopsy and MRD Monitoring — Cancer care is moving to blood draws, and dPCR counts tumour DNA at allele fractions qPCR can't see. Roche's April 2026 deal for SAGA Diagnostics, up to USD 595 Mn, shows what that's worth.
Wastewater and Outbreak Surveillance — Public health labs have made RT-dPCR their default for wastewater. CDC's network now takes data from about 1,500 U.S. sampling sites.
Cell and Gene Therapy Quality Control — Gene therapy makers need exact vector and residual-DNA counts for every batch. That's why pharma and biotech is the fastest-growing end user, at 15.59% a year.
Platform Consolidation and Multiplex Launches — Bio-Rad paid about USD 225 Mn for Stilla and launched four ddPCR platforms in July 2025. More colours and more samples per day widen the market dPCR can serve.
Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities.
What's Limiting the Digital PCR Market?
Academic Funding and Capex Pressure — University labs bought a large share of early dPCR systems, and their budgets are tight. Bio-Rad flagged academic headwinds from government funding cuts on its Q1 2025 call.
High Cost Per Sample Versus qPCR — dPCR still costs more per sample than qPCR and asks more of the lab. China's drug regulator itself cited expensive instruments and reagents when it approved the first dPCR kit.
Tariffs and Supply Chain Exposure — Most dPCR consumables are single-source and cross borders. Bio-Rad first put its 2025 tariff hit at up to 130 basis points of operating margin.
Despite these challenges, Vectomat Insights expects the market to grow from USD 1,843.6 Mn in 2025 to USD 5,206.5 Mn by 2035.
What Industry Leaders Are Saying About the Digital PCR Market
Digital PCR is the fastest-growing market within PCR, and its continued expansion into the clinical space, particularly oncology, is an upside for us.
We are proud to expand our partnership with Bio-Rad through this new agreement, demonstrating how our combined capabilities in mutation detection can address clinical needs with speed and precision, and opening doors to personalized, data-driven medicine.
We faced a challenging macroenvironment, with academic market headwinds due to government funding and global trade disruptions from tariffs.
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Product |
|
| By Application |
|
| By Technology |
|
| By End User |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the Digital PCR Market?
Key players operating in the Global Digital PCR market include Bio-Rad Laboratories (U.S.), QIAGEN (Netherlands), Thermo Fisher Scientific (U.S.), Roche (Switzerland), Stilla Technologies (France), Countable Labs (U.S.), Biodesix (U.S.), SAGA Diagnostics (Sweden), GENCURIX (South Korea), BioTNS (South Korea), Revosketch (South Korea) and Hamilton Company (U.S.). Bio-Rad is the droplet leader and widened its lead by buying Stilla in June 2025. QIAGEN's QIAcuity has passed 3,200 placements and the company is heading into private ownership under EQT. Roche is building a decentralised MRD offer around its Digital LightCycler and the SAGA deal. Countable Labs, backed by a USD 26 Mn round, is the challenger to watch.
What's New in the Digital PCR Market?
July 2025 — Bio-Rad Laboratories: Launched four new Droplet Digital PCR platforms, the QX Continuum system and the QX700 series acquired with Stilla Technologies, a week after closing the Stilla deal.
October 2025 — Biodesix: Expanded its partnership with Bio-Rad to develop, clinically validate and submit ddPCR IVD assays on the QX600, starting with the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer.
April 2026 — Roche (Foundation Medicine): Agreed to acquire SAGA Diagnostics, whose Pathlight MRD test combines whole-genome sequencing with digital PCR, for up to USD 595 Mn.
May 2026 — Countable Labs: Closed an oversubscribed USD 26 Mn financing round led by ARCH Venture Partners to fund clinical product development and global sales of Countable PCR.
May 2026 — QIAGEN: Made two custom QIAcuity digital PCR assays targeting the NP and VP35 regions of Bundibugyo ebolavirus available for research and wastewater surveillance.
October 2026 — QIAGEN: Agreed to an all-cash public takeover offer from EQT at EUR 46.50 per share, valuing the company at about EUR 10.8 Bn, with closing targeted for mid-2027.
Frequently Asked Questions
What is the size of the global digital PCR market?
The Global Digital PCR market was worth USD 1,843.6 Mn in 2025 and is forecast to reach USD 5,206.5 Mn by 2035, a 10.94% CAGR over 2026–2035. Droplet digital PCR is the largest technology at 61.6% of revenue, and North America is the largest region at 41.0%. Growth comes from liquid biopsy, wastewater surveillance and gene therapy quality control, according to Vectomat Insights.
Which region leads the digital PCR market?
North America leads with 41.0% of 2025 revenue, or USD 755.9 Mn, and the United States alone is worth USD 619.8 Mn. Europe follows at 24.74% and Asia Pacific at 23.81%, with Latin America at 5.0%, the Middle East at 3.07% and Africa at 2.38%. Asia Pacific is the fastest-growing region, led by South Korea's 13.1% CAGR, according to Vectomat Insights.
What is driving digital PCR market growth?
Four forces stand out: tumour DNA monitoring in cancer care, wastewater and outbreak surveillance, release testing for cell and gene therapies, and new multiplex platforms after a wave of acquisitions. Bio-Rad's July 2025 launch of four ddPCR systems and QIAGEN's 3,200-plus QIAcuity placements show vendors scaling up, while CDC's wastewater network now spans about 1,500 sampling sites, according to Vectomat Insights.
Which application segment is largest in the digital PCR market?
Oncology testing is the largest application, with 34.0% of 2025 revenue, or USD 626.8 Mn, because dPCR detects rare tumour mutations in blood. Infectious disease testing, at 30.0%, grows fastest at 14.58% a year and becomes the biggest application by 2035, at USD 2,156.3 Mn. Genetic disease testing holds 20.0%, and prenatal, reproductive and transplant monitoring holds 16.0%, according to Vectomat Insights.
Who are the key players in the digital PCR market?
The main companies are Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific and Roche, followed by Stilla Technologies, now part of Bio-Rad, and newer specialists such as Countable Labs, BioTNS and Revosketch. Clinical developers Biodesix, SAGA Diagnostics and GENCURIX build tests on these platforms, and Hamilton Company supplies automation. Bio-Rad leads, with droplet systems taking 61.6% of revenue, according to Vectomat Insights.
What restrains the digital PCR market?
Three restraints matter most. Academic research budgets are tight, so instrument sales grow at only 7.0% a year. Cost per sample is higher than qPCR, which keeps many routine tests on cheaper systems. Tariffs and proprietary consumables expose vendors to trade policy, and Bio-Rad first estimated a 2025 tariff hit of up to 130 basis points, according to Vectomat Insights.
Access the Complete Digital PCR Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312